Scholar Rock Holding annual total assets
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Total Assets Growth & History (SRRK)
Scholar Rock Holding's total assets was $404.3M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $404.3M | −$70.7M | −14.88% |
| 2024 | 2024-12-31 | $474.9M | $163.9M | +52.69% |
| 2023 | 2023-12-31 | $311.0M | −$47.1M | −13.16% |
| 2022 | 2022-12-31 | $358.2M | $53.7M | +17.65% |
| 2021 | 2021-12-31 | $304.4M | −$83.9M | −21.60% |
| 2020 | 2020-12-31 | $388.3M | $191.9M | +97.73% |
| 2019 | 2019-12-31 | $196.4M | $15.0M | +8.30% |
| 2018 | 2018-12-31 | $181.3M | $119.7M | +194.20% |
| 2017 | 2017-12-31 | $61.6M | — | — |
Scholar Rock Holding quarterly total assets
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $523.5M | $183.5M | +53.96% |
| Q1 2026 | 2026-03-31 | $535.3M | $127.7M | +31.33% |
| Q4 2025 | 2025-12-31 | $404.3M | −$70.7M | −14.88% |
| Q3 2025 | 2025-09-30 | $411.7M | $232.6M | +129.84% |
| Q2 2025 | 2025-06-30 | $340.0M | $113.2M | +49.89% |
| Q1 2025 | 2025-03-31 | $407.6M | $140.3M | +52.48% |
| Q4 2024 | 2024-12-31 | $474.9M | $163.9M | +52.69% |
| Q3 2024 | 2024-09-30 | $179.1M | −$71.6M | −28.54% |
| Q2 2024 | 2024-06-30 | $226.9M | −$58.0M | −20.37% |
| Q1 2024 | 2024-03-31 | $267.3M | −$47.4M | −15.07% |
| Q4 2023 | 2023-12-31 | $311.0M | −$47.1M | −13.16% |
| Q3 2023 | 2023-09-30 | $250.7M | −$139.6M | −35.77% |
| Q2 2023 | 2023-06-30 | $284.9M | −$139.2M | −32.83% |
| Q1 2023 | 2023-03-31 | $314.7M | $48.7M | +18.33% |
| Q4 2022 | 2022-12-31 | $358.2M | $53.7M | +17.65% |
| Q3 2022 | 2022-09-30 | $390.3M | $91.9M | +30.80% |
| Q2 2022 | 2022-06-30 | $424.1M | $92.1M | +27.73% |
| Q1 2022 | 2022-03-31 | $266.0M | −$94.6M | −26.24% |
| Q4 2021 | 2021-12-31 | $304.4M | −$83.9M | −21.60% |
| Q3 2021 | 2021-09-30 | $298.4M | $135.0M | +82.59% |
| Q2 2021 | 2021-06-30 | $332.1M | $175.7M | +112.36% |
| Q1 2021 | 2021-03-31 | $360.6M | $184.9M | +105.23% |
| Q4 2020 | 2020-12-31 | $388.3M | $191.9M | +97.73% |
| Q3 2020 | 2020-09-30 | $163.4M | −$25.1M | −13.32% |
| Q2 2020 | 2020-06-30 | $156.4M | −$40.6M | −20.59% |
| Q1 2020 | 2020-03-31 | $175.7M | $4.7M | +2.76% |
| Q4 2019 | 2019-12-31 | $196.4M | $15.0M | +8.30% |
| Q3 2019 | 2019-09-30 | $188.5M | $79.5M | +72.95% |
| Q2 2019 | 2019-06-30 | $196.9M | $77.9M | +65.50% |
| Q1 2019 | 2019-03-31 | $171.0M | — | — |
| Q4 2018 | 2018-12-31 | $181.3M | $119.7M | +194.20% |
| Q3 2018 | 2018-09-30 | $109.0M | — | — |
| Q2 2018 | 2018-06-30 | $119.0M | — | — |
| Q4 2017 | 2017-12-31 | $61.6M | — | — |
Scholar Rock Holding total assets trends
Over the last five fiscal years, Scholar Rock Holding's total assets increased from $388.3M to $404.3M, a change of $16.0M. The latest reported quarter, Q2 2026, shows $523.5M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...